MX2020012475A - Metodo para tratar el trastorno depresivo mayor. - Google Patents
Metodo para tratar el trastorno depresivo mayor.Info
- Publication number
- MX2020012475A MX2020012475A MX2020012475A MX2020012475A MX2020012475A MX 2020012475 A MX2020012475 A MX 2020012475A MX 2020012475 A MX2020012475 A MX 2020012475A MX 2020012475 A MX2020012475 A MX 2020012475A MX 2020012475 A MX2020012475 A MX 2020012475A
- Authority
- MX
- Mexico
- Prior art keywords
- depressive disorder
- major depressive
- treating major
- treating
- disorder
- Prior art date
Links
- 208000024714 major depressive disease Diseases 0.000 title 1
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 abstract 1
- 229960000450 esketamine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690419P | 2018-06-27 | 2018-06-27 | |
| US201862698323P | 2018-07-16 | 2018-07-16 | |
| US201862741564P | 2018-10-05 | 2018-10-05 | |
| US201862769264P | 2018-11-19 | 2018-11-19 | |
| PCT/IB2019/055453 WO2020003195A1 (en) | 2018-06-27 | 2019-06-27 | Method of treating major depressive disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012475A true MX2020012475A (es) | 2021-04-28 |
Family
ID=67909427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012475A MX2020012475A (es) | 2018-06-27 | 2019-06-27 | Metodo para tratar el trastorno depresivo mayor. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12036189B2 (https=) |
| EP (1) | EP3813807A1 (https=) |
| JP (2) | JP2021529732A (https=) |
| KR (1) | KR102793535B1 (https=) |
| CN (1) | CN112188889A (https=) |
| AU (1) | AU2019293515B2 (https=) |
| BR (1) | BR112020023882A2 (https=) |
| CA (1) | CA3103440A1 (https=) |
| IL (1) | IL278759B2 (https=) |
| MX (1) | MX2020012475A (https=) |
| WO (1) | WO2020003195A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE056378T2 (hu) | 2013-09-13 | 2022-02-28 | Univ Chiba Nat Univ Corp | R-Ketamin és sójának alkalmazása gyógyszerekként |
| ES2907692T3 (es) | 2017-12-29 | 2022-04-26 | Celon Pharma Sa | Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento |
| US11980595B2 (en) | 2018-02-15 | 2024-05-14 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| WO2019213551A1 (en) | 2018-05-04 | 2019-11-07 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| CN112702995A (zh) | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
| EP3863617A1 (en) | 2018-10-11 | 2021-08-18 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| EP4084786A1 (en) | 2019-12-30 | 2022-11-09 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| US7399488B2 (en) | 2002-07-05 | 2008-07-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| AU2007229866A1 (en) | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| AU2008286914B2 (en) | 2007-08-13 | 2014-10-02 | Ohemo Life Sciences Inc. | Abuse resistant drugs, method of use and method of making |
| JP2011520815A (ja) | 2008-05-09 | 2011-07-21 | エモリー・ユニバーシテイ | 精神神経障害治療のためのｎｍｄａ受容体拮抗薬 |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| WO2013138322A1 (en) | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| BR112015000150A2 (pt) | 2012-07-06 | 2017-06-27 | Egalet Ltd | composições farmacêuticas dissuasoras de abuso de liberação controlada |
| US20140079740A1 (en) | 2012-08-02 | 2014-03-20 | ClinPharm Support GmbH | Oral transmucosal adminstration forms of s-ketamine |
| US9468611B2 (en) | 2012-09-27 | 2016-10-18 | Relmada Therapeutics, Inc. | d-Methadone for the treatment of psychiatric symptoms |
| US10555916B2 (en) | 2013-01-25 | 2020-02-11 | Case Western Reserve University | NMDAR antagonist for the treatment of pervasive development disorders |
| DK2983787T3 (da) | 2013-04-12 | 2020-01-06 | Icahn School Med Mount Sinai | Fremgangsmåde til behandling af posttraumatisk stresssygdom |
| CA2922507C (en) | 2013-08-26 | 2022-07-05 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| WO2015051259A1 (en) | 2013-10-04 | 2015-04-09 | Impax Laboratories, Inc. | Pharmaceutical compositions and methods of use |
| EA032013B1 (ru) | 2013-10-31 | 2019-03-29 | Сайма Лэбс Инк. | Препятствующие злоупотреблению гранулированные лекарственные формы с немедленным высвобождением |
| PL3287124T3 (pl) | 2014-04-17 | 2023-02-20 | Ketabon Gmbh | Doustna postać dawkowania ketaminy |
| AU2015318123A1 (en) * | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| DK3215147T3 (da) | 2014-11-04 | 2024-04-02 | Acadia Pharm Inc | Neurodæmpende norketamin-forbindelser og fremgangsmåder |
| WO2016094358A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| WO2017041112A1 (en) | 2015-09-04 | 2017-03-09 | Cyprus Therapeutics, Inc. | Ketamine and cytochrome p 450 inhibitor combinations |
| US11110070B2 (en) | 2015-11-17 | 2021-09-07 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms |
| AU2017351437B2 (en) | 2016-10-27 | 2022-01-27 | National University Corporation Chiba University | Application of (S)-norketamine and salt thereof as pharmaceutical |
| ES2991544T3 (es) | 2016-11-30 | 2024-12-04 | Wolfson Philip E | Ketamina para el tratamiento de síntomas relacionados con la menstruación |
| WO2018234568A2 (en) | 2017-06-23 | 2018-12-27 | Develco Pharma Schweiz Ag | HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION |
| CN111630026A (zh) | 2017-10-10 | 2020-09-04 | 道格拉斯制药有限公司 | 缓释药物制剂和治疗方法 |
| KR20240011237A (ko) | 2017-12-22 | 2024-01-25 | 얀센 파마슈티카 엔브이 | 우울증 치료를 위한 에스케타민 |
| CN112702995A (zh) | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
| CA3133012A1 (en) | 2019-08-05 | 2021-02-11 | The Ketamine Research Foundation | Ketamine for the treatment of postpartum symptoms and disorders |
| TW202135787A (zh) | 2019-12-12 | 2021-10-01 | 比利時商健生藥品公司 | 艾氯胺酮調配物及製備與儲存的方法 |
| EP4084786A1 (en) | 2019-12-30 | 2022-11-09 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
-
2019
- 2019-06-27 BR BR112020023882-1A patent/BR112020023882A2/pt unknown
- 2019-06-27 IL IL278759A patent/IL278759B2/en unknown
- 2019-06-27 AU AU2019293515A patent/AU2019293515B2/en active Active
- 2019-06-27 US US16/454,399 patent/US12036189B2/en active Active
- 2019-06-27 KR KR1020207036721A patent/KR102793535B1/ko active Active
- 2019-06-27 EP EP19766075.6A patent/EP3813807A1/en active Pending
- 2019-06-27 JP JP2020569956A patent/JP2021529732A/ja active Pending
- 2019-06-27 CA CA3103440A patent/CA3103440A1/en active Pending
- 2019-06-27 MX MX2020012475A patent/MX2020012475A/es unknown
- 2019-06-27 WO PCT/IB2019/055453 patent/WO2020003195A1/en not_active Ceased
- 2019-06-27 CN CN201980034997.3A patent/CN112188889A/zh active Pending
-
2024
- 2024-01-09 JP JP2024000939A patent/JP2024041855A/ja active Pending
- 2024-07-15 US US18/772,474 patent/US20240366530A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200000748A1 (en) | 2020-01-02 |
| AU2019293515B2 (en) | 2024-10-24 |
| IL278759B1 (en) | 2024-08-01 |
| KR102793535B1 (ko) | 2025-04-11 |
| IL278759A (en) | 2021-01-31 |
| JP2024041855A (ja) | 2024-03-27 |
| WO2020003195A1 (en) | 2020-01-02 |
| US20240366530A1 (en) | 2024-11-07 |
| AU2019293515A1 (en) | 2020-12-03 |
| JP2021529732A (ja) | 2021-11-04 |
| IL278759B2 (en) | 2024-12-01 |
| BR112020023882A2 (pt) | 2021-02-09 |
| KR20210028159A (ko) | 2021-03-11 |
| CN112188889A (zh) | 2021-01-05 |
| EP3813807A1 (en) | 2021-05-05 |
| CA3103440A1 (en) | 2020-01-02 |
| US12036189B2 (en) | 2024-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020012475A (es) | Metodo para tratar el trastorno depresivo mayor. | |
| MX2021010193A (es) | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. | |
| PH12019501373A1 (en) | Methods of treating cochlears synaptopathy | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| MX2018011114A (es) | Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías. | |
| MX2021003903A (es) | Terapia combinada para el melanoma. | |
| EP4574201A3 (en) | Magnetic stimulation devices for therapeutic treatments | |
| MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
| WO2017139570A8 (en) | Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccine | |
| MX2021006326A (es) | Inhibidores de pcna. | |
| EA201991818A1 (ru) | Лечение рака | |
| ZA201807438B (en) | Methods of treating ocular conditions | |
| PH12018501455A1 (en) | Therapeutic compostions and methods for treating hepatitis b | |
| NZ755301A (en) | Cancer treatment | |
| PH12018550186A1 (en) | Pharmaceutical combinations for treating cancer | |
| MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
| MX2019006552A (es) | Terapia génica para mucopolisacaridosis de tipo i. | |
| MX2019002108A (es) | Terapia de combinacion con inhibidores de glutaminasa. | |
| MX2022006751A (es) | Minitrampas de vegf y metodos de uso de las mismas. | |
| AU2018337076A1 (en) | Method of treatment | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| PH12018502318A1 (en) | Compositions and methods for treatment of inflammation of infection of the eye | |
| MX2022013383A (es) | Composiciones y metodo para tratar la depresion. | |
| PH12017500275A1 (en) | Methods of treating depression using nmda modulators | |
| MX2017009632A (es) | Tratamiento conjunto usando conjugado anticuerpo-farmaco dirigido a (cd-19) y vincristina. |